Recursion Pharmaceuticals에 대한 매도 수량은 투자자에게 Recursion Pharmaceuticals의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Recursion Pharmaceuticals (NASDAQ:RXRX) 주식, 공매도 수량 보고

Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Equities

News

Markets

ARKQ

BLDE

TDOC

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 팔란티어 테크놀로지스(NYSE:PLTR)에 주목할 만한 투자를 했다. 이는 인공 지능(AI) 부문이 탄력을 받으면서 이루어진 움직임이다.

캐시 우드의 아크 인베스트는 AI 열풍 속에서 516만 달러 가치의 팔란티어 주식 매수

Biotech

Offerings

After-Hours Center

Movers

NVDA

리커전 파마슈티컬스(NASDAQ:RXRX)의 주가는 회사가 보통주 공모 제안을 발표한 후 수요일 시간외 거래에서 하락했다. 사건의 전말 (What Happened): 수요일 시장이 마감된 후 리커전은 인수된 공모를 통해 2억 달러 상당의 보통주를 제공 및 판매할 계획이라고 밝혔다. 모든 주식은 리커전에서 제공된다.

리커전 파마슈티컬스: 2억 달러 상당 공모 제안 발표 후 주가 하락

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) lowers FY2024 GAAP EPS guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 analyst estimate..

Guidance

HLIO

Helios Technologies Lowers FY2024 GAAP EPS Guidance from $1.35-1.55 to $1.15-1.25 vs $1.41 Est

SMCI

Supermicro Sees Q2 FY2025 Net Sales $5.5B-$6.1B, GAAP EPS $0.48-$0.58, Non-GAAP EPS $0.56-$0.65

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is unchanged from the same period last year. The company reported quarterly sales of $150.50 million which missed the analyst consensus estimate of $152.30 million by 1.18 percent. This is a 6.40 percent decrease over sales of $160.78 million the same period last year.

Earnings

Earnings Misses

SWIM

Latham Group Q3 EPS $0.05 Misses $0.06 Estimate, Sales $150.50M Miss $152.30M Estimate

QLYS

Qualys Raises 2024 Adj EPS Guidance From $5.46- $5.62 To $5.81 - $5.91 (Est $5.57), Lifts Revenue Guidance From $597.5M - $601.5M To $602.9M - $605.9M (Est $599.362M)

InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) affirms FY2025 sales outlook from $815.00 million-865.00 million to $815.00 million-865.00 million.

INNV

InnovAge Holding Affirms FY2025 Sales Guidance to $815.00M-865.00M  VS Est. 844.27M

MCHP

Microchip Sees Q3 2024 Net Sales $1.025B-$1.095B

Super Micro Computer Expects To Report Prelim. Q1 Net Sales $5.9B-$6B (Prior $6B-$7B) , Non-GAAP EPS $0.75-$0.76 (Prior $0.67-$0.83)

trivago (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVG#NASDAQ">TRVG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.02 by 300 percent. The company reported quarterly sales of $160.565 million which beat the analyst consensus estimate of $154.280 million by 4.07 percent. This is a 6.55 percent decrease over sales of $171.825 million the same period last year.

Earnings Beats

TRVG

trivago Q3 2024 GAAP EPS $(0.04) Misses $0.02 Estimate, Sales $160.565M Beat $154.280M Estimate

2024 Outlook
The company now expects:
<ul>
<li>Adjusted EBITDA, excluding reportable catastrophes6, to increase low double-digits, led by strong growth in Global Housing, with modest growth in Global Lifestyle.</li>
<li>Adjusted earnings, excluding reportable catastrophes, per diluted share6, to increase mid- to high-teens. Note: The metrics included within the company's outlook are non-GAAP financial measures and the company believes that it cannot, without unreasonable efforts, forecast certain information needed to reconcile to the GAAP measures, the probable significance of which cannot be determined. More information can be found in the Non-GAAP Financial Measures section.</li>
</ul>

Assurant Sees FY24 Adjusted EBITDA, Excluding Reportable Catastrophes, To Increase Low Double-Digits, Led By Strong Growth In Global Housing, With Modest Growth In Global Lifestyle; Adjusted Earnings, Excluding Reportable Catastrophes, Per Diluted Share, To Increase Mid- To High-Teens

InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $205.14 million which beat the analyst consensus estimate of $203.33 million by 0.89 percent. This is a 12.42 percent increase over sales of $182.49 million the same period last year.

InnovAge Holding Q1 EPS $(0.04), Inline, Sales $205.14M Beat $203.33M Estimate

Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.52 by 19.05 percent. This is a 30.07 percent decrease over earnings of $4.29 per share from the same period last year. The company reported quarterly sales of $2.97 billion which beat the analyst consensus estimate of $2.94 billion by 0.94 percent. This is a 6.98 percent increase over sales of $2.77 billion the same period last year.

Assurant Q3 Adj $3.00 Beats $2.52 Estimate, Sales $2.97B Beat $2.94B Estimate

Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.43 by 6.98 percent. The company reported quarterly sales of $1.164 billion which beat the analyst consensus estimate of $1.152 billion by 1.01 percent. This is a 48.36 percent decrease over sales of $2.254 billion the same period last year.

Microchip Technology Q2 2025 Adj. EPS $0.46 Beats $0.43 Estimate, Sales $1.164B Beat $1.152B Estimate

Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) reported quarterly sales of $354.40 million which missed the analyst consensus estimate of $402.87 million by 12.03 percent. This is a 9.68 percent decrease over sales of $392.37 million the same period last year.

INFN

Infinera Q3 Sales $354.40M Miss $402.87M Estimate

CTKB

Cytek Biosciences Sees FY24 Revenue $203M-$210M Vs $203.937M; Sees 5-9% Revenue Growth

US Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USPH#NYSE">USPH</a>) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.68 by 1.47 percent. This is a 11.29 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $168.033 million which beat the analyst consensus estimate of $164.381 million by 2.22 percent. This is a 12.02 percent increase over sales of $150.007 million the same period last year.

USPH

US Physical Therapy Q3 2024 Adj. EPS $0.69 Beats $0.68 Estimate, Sales $168.033M Beat $164.381M Estimate

LUMN

Lumen Technologies Continues To Expect FY24 Adjusted EBITDA Of $3.9B - $4.0B, Net Cash Interest Of $1.15B - $1.25B

Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) reported quarterly earnings of $3.42 per share which beat the analyst consensus estimate of $2.93 by 16.72 percent. The company reported quarterly sales of $253.912 million which missed the analyst consensus estimate of $278.980 million by 8.99 percent. This is a 11.73 percent increase over sales of $227.250 million the same period last year.

GPOR

Gulfport Energy Q3 2024 Adj. EPS $3.42 Beats $2.93 Estimate, Sales $253.912M Miss $278.980M Estimate

Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) lowers FY2024 sales outlook from $60.00 million-90.00 million to $15.00 million.

EOSE

Eos Energy Enterprises Lowers FY2024 Sales Guidance from $60.00M-90.00M to $15.00M  VS Est. 62.33M

Macrogenics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.21 by 328.57 percent. This is a 221.43 percent increase over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $110.71 million which beat the analyst consensus estimate of $76.11 million by 45.46 percent. This is a 964.81 percent increase over sales of $10.40 million the same period last year.

MGNX

Macrogenics Q3 EPS $0.90 Beats $0.21 Estimate, Sales $110.71M Beat $76.11M Estimate

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.34 by 14.71 percent. This is a 34.09 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $102.527 million which beat the analyst consensus estimate of $101.944 million by 0.57 percent. This is a 9.61 percent decrease over sales of $113.431 million the same period last year.

FORR

Forrester Res Q3 2024 Adj. EPS $0.29 Misses $0.34 Estimate, Sales $102.527M Beat $101.944M Estimate

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Interest Rate Regimes And ARKG: Underperformance Explained

Why Recursion is getting love as an AI and drug discovery top pick

Recursion, Exscientia seek support for merger ahead of special meeting

Recursion announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecul...

Recursion Pharmaceuticals doses first patient in Phase 2 trial of REC-3964

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 5,540 calls trading, 2x expected, and implied vol increasing over 2 points to...

Recursion Pharmaceuticals call volume above normal and directionally bullish

20:11 EDT Cathie Wood's ARK Investment buys 331K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 331K shares of Recursion Pharmaceuticals today

20:11 EDT Cathie Wood's ARK Investment buys 729K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 729K shares of Recursion Pharmaceuticals today

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2024 Update

20:20 EST Cathie Wood's ARK Investment buys 106K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 106K shares of Recursion Pharmaceuticals today

AMGN

ARKB

ARKF

ARKW

ARKX

BEAM

BIIB

BLUE

BMYMP

DKNG

EDIT

EXAI

EXAS

GNOM

GOOG

GOOGL

HELX

IDNA

NTLA

PACB

SDGR

Legal

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Health Care

General

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Opinion

AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, ARC, RXRX on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, RVNC, K, RXRX on Behalf of Shareholders

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

Comments

Recursion Pharmaceuticals

매도 수량

Recursion Pharmaceuticals (NASDAQ:RXRX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌